Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Page standards status: Informative |
version: 2; Last updated: 2026-05-30 21:56:03+0000
Profile: M11ReportSection04
ArtifactPublicationStatus: Active
url: https://fevir.net/resources/Composition/568061
identifier: FEvIR Object Identifier/568061
status: Final
type: CeSHarP Report
category: section4-trial-design
date: 2026-05-30 21:56:03+0000
author: Brian S. Alper, MD, MSPH
title: M11 Report Section 4 (Trial Design) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
custodian: Computable Publishing LLC
relatesTo
type: Derived From
target: A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
relatesTo
type: Cite As
target:
M11 Report Section 4 (Trial Design) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example [Database Entry: FHIR Composition Resource]. Contributors: Brian S. Alper, MD, MSPH [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 568061. Revised 2026-05-30. Available at: https://fevir.net/resources/Composition/568061. Computable resource at: https://fevir.net/resources/Composition/568061#json.